Cargando…

Recurrent tuberculosis in the Netherlands – a 24-year follow-up study, 1993 to 2016

BACKGROUND: Not all treated tuberculosis (TB) patients achieve long-term recovery and reactivation rates reflect effectiveness of TB treatment. AIM: We aimed to estimate rates and risk factors of TB reactivation and reinfection in patients treated in the Netherlands, after completed or interrupted t...

Descripción completa

Detalles Bibliográficos
Autores principales: Erkens, Connie, Tekeli, Betül, van Soolingen, Dick, Schimmel, Henrieke, Verver, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950855/
https://www.ncbi.nlm.nih.gov/pubmed/35332864
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.12.2100183
_version_ 1784675242947379200
author Erkens, Connie
Tekeli, Betül
van Soolingen, Dick
Schimmel, Henrieke
Verver, Suzanne
author_facet Erkens, Connie
Tekeli, Betül
van Soolingen, Dick
Schimmel, Henrieke
Verver, Suzanne
author_sort Erkens, Connie
collection PubMed
description BACKGROUND: Not all treated tuberculosis (TB) patients achieve long-term recovery and reactivation rates reflect effectiveness of TB treatment. AIM: We aimed to estimate rates and risk factors of TB reactivation and reinfection in patients treated in the Netherlands, after completed or interrupted treatment. METHODS: Retrospective cohort study of TB patients with available DNA fingerprint data, registered in the Netherlands Tuberculosis register (NTR) between 1993 and 2016. Reactivation was defined as an identical, and reinfection as a non-identical Mycobacterium tuberculosis strain in sequential episodes. RESULTS: Reactivation rate was 55/100,000 person-years (py) for patients who completed, and 318/100,000 py for patients who interrupted treatment. The risk of reactivation was highest in the first 5 years after treatment in both groups. The incidence rate of reactivation was 228/100,000 py in the first 2 years and 57/100,000 py 2–5 years after completed treatment. The overall rate of reinfection was 16/100,000 py. Among those who completed treatment, patients with male sex, mono or poly rifampicin-resistant TB and a previous TB episode had significantly higher risk of reactivation. Extrapulmonary TB was associated with a lower risk. Among patients who interrupted treatment, directly observed treatment (DOT) and being an undocumented migrant or people experiencing homelessness were associated with a higher risk of reactivation. CONCLUSIONS: Both patients who completed or interrupted TB treatment should be considered as risk groups for reactivation for at least 2–5 years after treatment. They patients should be monitored and guidelines should be in place to enhance early detection of recurrent TB.
format Online
Article
Text
id pubmed-8950855
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-89508552022-04-11 Recurrent tuberculosis in the Netherlands – a 24-year follow-up study, 1993 to 2016 Erkens, Connie Tekeli, Betül van Soolingen, Dick Schimmel, Henrieke Verver, Suzanne Euro Surveill Research BACKGROUND: Not all treated tuberculosis (TB) patients achieve long-term recovery and reactivation rates reflect effectiveness of TB treatment. AIM: We aimed to estimate rates and risk factors of TB reactivation and reinfection in patients treated in the Netherlands, after completed or interrupted treatment. METHODS: Retrospective cohort study of TB patients with available DNA fingerprint data, registered in the Netherlands Tuberculosis register (NTR) between 1993 and 2016. Reactivation was defined as an identical, and reinfection as a non-identical Mycobacterium tuberculosis strain in sequential episodes. RESULTS: Reactivation rate was 55/100,000 person-years (py) for patients who completed, and 318/100,000 py for patients who interrupted treatment. The risk of reactivation was highest in the first 5 years after treatment in both groups. The incidence rate of reactivation was 228/100,000 py in the first 2 years and 57/100,000 py 2–5 years after completed treatment. The overall rate of reinfection was 16/100,000 py. Among those who completed treatment, patients with male sex, mono or poly rifampicin-resistant TB and a previous TB episode had significantly higher risk of reactivation. Extrapulmonary TB was associated with a lower risk. Among patients who interrupted treatment, directly observed treatment (DOT) and being an undocumented migrant or people experiencing homelessness were associated with a higher risk of reactivation. CONCLUSIONS: Both patients who completed or interrupted TB treatment should be considered as risk groups for reactivation for at least 2–5 years after treatment. They patients should be monitored and guidelines should be in place to enhance early detection of recurrent TB. European Centre for Disease Prevention and Control (ECDC) 2022-03-24 /pmc/articles/PMC8950855/ /pubmed/35332864 http://dx.doi.org/10.2807/1560-7917.ES.2022.27.12.2100183 Text en This article is copyright of the authors or their affiliated institutions, 2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Research
Erkens, Connie
Tekeli, Betül
van Soolingen, Dick
Schimmel, Henrieke
Verver, Suzanne
Recurrent tuberculosis in the Netherlands – a 24-year follow-up study, 1993 to 2016
title Recurrent tuberculosis in the Netherlands – a 24-year follow-up study, 1993 to 2016
title_full Recurrent tuberculosis in the Netherlands – a 24-year follow-up study, 1993 to 2016
title_fullStr Recurrent tuberculosis in the Netherlands – a 24-year follow-up study, 1993 to 2016
title_full_unstemmed Recurrent tuberculosis in the Netherlands – a 24-year follow-up study, 1993 to 2016
title_short Recurrent tuberculosis in the Netherlands – a 24-year follow-up study, 1993 to 2016
title_sort recurrent tuberculosis in the netherlands – a 24-year follow-up study, 1993 to 2016
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950855/
https://www.ncbi.nlm.nih.gov/pubmed/35332864
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.12.2100183
work_keys_str_mv AT erkensconnie recurrenttuberculosisinthenetherlandsa24yearfollowupstudy1993to2016
AT tekelibetul recurrenttuberculosisinthenetherlandsa24yearfollowupstudy1993to2016
AT vansoolingendick recurrenttuberculosisinthenetherlandsa24yearfollowupstudy1993to2016
AT schimmelhenrieke recurrenttuberculosisinthenetherlandsa24yearfollowupstudy1993to2016
AT verversuzanne recurrenttuberculosisinthenetherlandsa24yearfollowupstudy1993to2016